Anemia medicine

Reading File
Finding Sources
Finding Sources
Searching Images

anemia classification types diagram

Educational diagram illustrating the Judet-Letournel classification of acetabular fractures using anatomical specimens of the hemipelvis. The visual is divided into two rows: 'Elementary' and 'Associated' fracture types. White lines superimposed on the specimens delineate specific fracture patterns. The 'Elementary' row features five simple patterns: Anterior column (vertical line through the pelvic brim), Anterior wall (localized articular segment), Posterior column (ischiadic notch through obturator foramen), Posterior wall (localized posterior rim), and Transverse (horizontal line bisecting the acetabulum). The 'Associated' row demonstrates complex configurations: Both column, Transverse plus posterior wall, Posterior column plus posterior wall, Anterior column with posterior hemitransverse (a vertical anterior column line joined by a horizontal posterior component), and T-type (a transverse fracture with an additional vertical stem extending through the obturator foramen). This orthopedic diagram serves as a clinical reference for orthopedic surgeons and medical students to understand pelvic trauma morphology and surgical planning.

Educational diagram illustrating the Judet-Letournel classification of acetabular fractures using anatomical specimens of the hemipelvis. The visual is divided into two rows: 'Elementary' and 'Associated' fracture types. White lines superimposed on the specimens delineate specific fracture patterns. The 'Elementary' row features five simple patterns: Anterior column (vertical line through the pelvic brim), Anterior wall (localized articular segment), Posterior column (ischiadic notch through obturator foramen), Posterior wall (localized posterior rim), and Transverse (horizontal line bisecting the acetabulum). The 'Associated' row demonstrates complex configurations: Both column, Transverse plus posterior wall, Posterior column plus posterior wall, Anterior column with posterior hemitransverse (a vertical anterior column line joined by a horizontal posterior component), and T-type (a transverse fracture with an additional vertical stem extending through the obturator foramen). This orthopedic diagram serves as a clinical reference for orthopedic surgeons and medical students to understand pelvic trauma morphology and surgical planning.

This orthopaedic anatomical diagram illustrates the Chiron classification (2004) for femoral head fractures, shown across five categorized types (Type I to Type V). Each type is presented using a dry bone model of the proximal femur from two perspectives: a lateral/oblique view and a frontal view of the femoral head. Fracture lines are demarcated by solid black lines to indicate the morphology and size of the fracture fragments. Type I displays small osteochondral fragments at the superior-lateral aspect. Type II shows a 1/4 head fragment on the anterior-superior surface. Type III demonstrates a 1/3 head fragment extending from superior to posterior. Type IV depicts a vertical fracture dividing approximately 1/2 of the femoral head. Type V illustrates cranial cartilage impaction with multiple intersecting lines across the superior articular surface. The classification is clinically relevant for orthopedic surgeons and residents for determining the severity of femoral head trauma and informing surgical decisions, such as fragment fixation versus excision based on size and location.

This orthopaedic anatomical diagram illustrates the Chiron classification (2004) for femoral head fractures, shown across five categorized types (Type I to Type V). Each type is presented using a dry bone model of the proximal femur from two perspectives: a lateral/oblique view and a frontal view of the femoral head. Fracture lines are demarcated by solid black lines to indicate the morphology and size of the fracture fragments. Type I displays small osteochondral fragments at the superior-lateral aspect. Type II shows a 1/4 head fragment on the anterior-superior surface. Type III demonstrates a 1/3 head fragment extending from superior to posterior. Type IV depicts a vertical fracture dividing approximately 1/2 of the femoral head. Type V illustrates cranial cartilage impaction with multiple intersecting lines across the superior articular surface. The classification is clinically relevant for orthopedic surgeons and residents for determining the severity of femoral head trauma and informing surgical decisions, such as fragment fixation versus excision based on size and location.

This educational infographic details the Echinococcus multilocularis Ulm Classification for Computed Tomography (EMUC-CT), a standardized system for evaluating hepatic Alveolar Echinococcosis (AE). The diagram is divided into two sections: Primary Morphology and Patterns of Calcification.

The left section illustrates five morphological types (I-V) using axial CT cross-sections of the liver. Type I (diffuse infiltrating) and Type II (primarily circumscribed, tumor-like) are sub-categorized by the presence or absence of a cystoid portion. Type III (primarily cystoid) distinguishes between intermediate and widespread involvement, further categorized by solid peripheral portions. Type IV displays small-cystoid, metastasis-like lesions, while Type V represents mainly calcified, inactive lesions.

The right panel illustrates six distinct calcification patterns within hepatic lesions: feathery (branching), focal (isolated spots), diffuse (widespread), edge-weighted (peripheral), and central. The classification system is designed to improve diagnostic accuracy and clinical assessment of disease activity in patients with Alveolar Echinococcosis.

This educational infographic details the Echinococcus multilocularis Ulm Classification for Computed Tomography (EMUC-CT), a standardized system for evaluating hepatic Alveolar Echinococcosis (AE). The diagram is divided into two sections: Primary Morphology and Patterns of Calcification. The left section illustrates five morphological types (I-V) using axial CT cross-sections of the liver. Type I (diffuse infiltrating) and Type II (primarily circumscribed, tumor-like) are sub-categorized by the presence or absence of a cystoid portion. Type III (primarily cystoid) distinguishes between intermediate and widespread involvement, further categorized by solid peripheral portions. Type IV displays small-cystoid, metastasis-like lesions, while Type V represents mainly calcified, inactive lesions. The right panel illustrates six distinct calcification patterns within hepatic lesions: feathery (branching), focal (isolated spots), diffuse (widespread), edge-weighted (peripheral), and central. The classification system is designed to improve diagnostic accuracy and clinical assessment of disease activity in patients with Alveolar Echinococcosis.

This medical illustration presents the Paley classification system for tibial hemimelia, a congenital lower limb deficiency. The diagram categorizes the condition into five primary types (I-V) based on the degree of tibial deficiency and associated joint anomalies, with several subtypes. Type I illustrates a hypoplastic but present tibia. Type II (A-C) shows various distal tibial dysplasias, including delta tibia and cartilaginous anlagen. Type III (A-B) demonstrates distal tibiofibular diastasis with a missing tibial plafond. Type IV (A-B) depicts distal tibial aplasia where only a proximal tibial remnant exists. Type V (A-C) represents complete tibial aplasia, further classified by the presence or absence of the patella and quadriceps function. Lateral views accompany several types to show the sagittal alignment of the knee and the equinovarus positioning of the foot. The illustration serves as a diagnostic and surgical planning tool for pediatric orthopedics, highlighting the relationship between the remnant tibia, the fibula, and the foot position.

This medical illustration presents the Paley classification system for tibial hemimelia, a congenital lower limb deficiency. The diagram categorizes the condition into five primary types (I-V) based on the degree of tibial deficiency and associated joint anomalies, with several subtypes. Type I illustrates a hypoplastic but present tibia. Type II (A-C) shows various distal tibial dysplasias, including delta tibia and cartilaginous anlagen. Type III (A-B) demonstrates distal tibiofibular diastasis with a missing tibial plafond. Type IV (A-B) depicts distal tibial aplasia where only a proximal tibial remnant exists. Type V (A-C) represents complete tibial aplasia, further classified by the presence or absence of the patella and quadriceps function. Lateral views accompany several types to show the sagittal alignment of the knee and the equinovarus positioning of the foot. The illustration serves as a diagnostic and surgical planning tool for pediatric orthopedics, highlighting the relationship between the remnant tibia, the fibula, and the foot position.

Finding Sources
Finding Sources
Finding Sources
Searching Images

iron deficiency anemia peripheral blood smear

Peripheral blood smear from a patient with known chronic lymphocytic leukemia (CLL) showing autoimmune hemolytic anemia (AIHA). Brightfield microscopy of Wright-Giemsa stained smear at 1000x (oil immersion) reveals two dominant cell populations: numerous small mature lymphocytes typical of CLL and red blood cells showing spherocytic deformation. A smudge cell is evident just left of center, a classical clue for CLL. Red cells display reduced central pallor consistent with spherocytes, indicating intravascular or extravascular hemolysis driven by autoantibodies. The background shows mild polychromasia and rare nucleated RBCs, consistent with a robust reticulocyte response; the corrected reticulocyte count in this case is markedly elevated (>7%). Platelets are not significantly abnormal. These features collectively support autoimmune destruction of erythrocytes in the setting of CLL. Diagnostic significance lies in recognizing AIHA as a common autoimmune complication in CLL, with a clinical picture of sudden Hb decline and compensatory erythropoiesis. Differential considerations include drug-induced hemolysis, other causes of hemolytic anemia, or marrow infiltration by CLL. Clinical correlation includes therapy implications (steroids, rituximab) and close monitoring of hemolysis markers. This image is a valuable teaching resource for hematology morphology, AIHA in CLL, and differential diagnosis in anemia.

Peripheral blood smear from a patient with known chronic lymphocytic leukemia (CLL) showing autoimmune hemolytic anemia (AIHA). Brightfield microscopy of Wright-Giemsa stained smear at 1000x (oil immersion) reveals two dominant cell populations: numerous small mature lymphocytes typical of CLL and red blood cells showing spherocytic deformation. A smudge cell is evident just left of center, a classical clue for CLL. Red cells display reduced central pallor consistent with spherocytes, indicating intravascular or extravascular hemolysis driven by autoantibodies. The background shows mild polychromasia and rare nucleated RBCs, consistent with a robust reticulocyte response; the corrected reticulocyte count in this case is markedly elevated (>7%). Platelets are not significantly abnormal. These features collectively support autoimmune destruction of erythrocytes in the setting of CLL. Diagnostic significance lies in recognizing AIHA as a common autoimmune complication in CLL, with a clinical picture of sudden Hb decline and compensatory erythropoiesis. Differential considerations include drug-induced hemolysis, other causes of hemolytic anemia, or marrow infiltration by CLL. Clinical correlation includes therapy implications (steroids, rituximab) and close monitoring of hemolysis markers. This image is a valuable teaching resource for hematology morphology, AIHA in CLL, and differential diagnosis in anemia.

This composite image consists of clinical photographs and a diagnostic peripheral blood smear. Figure 1a (left) shows a pediatric patient with clinical signs including total alopecia (complete absence of scalp hair) and nail pitting affecting both hands and feet, characterized by small punctate depressions on the nail plates. Figure 1b (right) is a microscopic view of a peripheral blood smear demonstrating microangiopathic hemolytic anemia. Visible are numerous schistocytes—fragmented, irregular red blood cells including helmet cells and triangular forms—alongside some normal erythrocytes showing central pallor. The educational focus is on the multi-systemic manifestations of a medical condition, likely a microangiopathic process such as Hemolytic Uremic Syndrome (HUS) or similar systemic pathology, illustrating the correlation between dermatological signs (hair and nail changes) and hematological abnormalities (hemolysis and schistocytosis).

This composite image consists of clinical photographs and a diagnostic peripheral blood smear. Figure 1a (left) shows a pediatric patient with clinical signs including total alopecia (complete absence of scalp hair) and nail pitting affecting both hands and feet, characterized by small punctate depressions on the nail plates. Figure 1b (right) is a microscopic view of a peripheral blood smear demonstrating microangiopathic hemolytic anemia. Visible are numerous schistocytes—fragmented, irregular red blood cells including helmet cells and triangular forms—alongside some normal erythrocytes showing central pallor. The educational focus is on the multi-systemic manifestations of a medical condition, likely a microangiopathic process such as Hemolytic Uremic Syndrome (HUS) or similar systemic pathology, illustrating the correlation between dermatological signs (hair and nail changes) and hematological abnormalities (hemolysis and schistocytosis).

Peripheral blood smear prepared with Wright-Giemsa stain and examined under brightfield illumination using a 100× oil immersion objective reveals a single large plasma cell among a field of mature erythrocytes. The plasma cell displays features typical of clonal plasma cells: basophilic cytoplasm, an eccentrically placed round nucleus, and a conspicuous perinuclear hof; background shows rouleaux formation of red cells. This image exemplifies hematologic involvement by a plasma cell dyscrasia. In plasma cell leukemia, circulating plasma cells constitute more than 20% of leukocytes, a hallmark distinguishing it from conventional multiple myeloma, although both conditions share monoclonal plasma cell proliferation. The presence of circulating plasma cells is associated with younger patient age, higher incidence of anemia, thrombocytopenia, organomegaly, and possible lymphadenopathy; however lytic bone lesions may be less common. Immunophenotypic patterns often include lack of CD56 expression relative to myeloma. Clinically, this morphological finding warrants confirmation with complete blood count, peripheral smear review, quantitative plasma cell percentage, serum protein electrophoresis, and immunofixation to identify monoclonal immunoglobulin isotype (IgD/IgE or light-chain predominance). Early detection of circulating plasma cells supports prognosis assessment and guides therapy decisions in plasma cell dyscrasia management and monitoring, including risk stratification and treatment response evaluation for practice in clinics.

Peripheral blood smear prepared with Wright-Giemsa stain and examined under brightfield illumination using a 100× oil immersion objective reveals a single large plasma cell among a field of mature erythrocytes. The plasma cell displays features typical of clonal plasma cells: basophilic cytoplasm, an eccentrically placed round nucleus, and a conspicuous perinuclear hof; background shows rouleaux formation of red cells. This image exemplifies hematologic involvement by a plasma cell dyscrasia. In plasma cell leukemia, circulating plasma cells constitute more than 20% of leukocytes, a hallmark distinguishing it from conventional multiple myeloma, although both conditions share monoclonal plasma cell proliferation. The presence of circulating plasma cells is associated with younger patient age, higher incidence of anemia, thrombocytopenia, organomegaly, and possible lymphadenopathy; however lytic bone lesions may be less common. Immunophenotypic patterns often include lack of CD56 expression relative to myeloma. Clinically, this morphological finding warrants confirmation with complete blood count, peripheral smear review, quantitative plasma cell percentage, serum protein electrophoresis, and immunofixation to identify monoclonal immunoglobulin isotype (IgD/IgE or light-chain predominance). Early detection of circulating plasma cells supports prognosis assessment and guides therapy decisions in plasma cell dyscrasia management and monitoring, including risk stratification and treatment response evaluation for practice in clinics.

Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information to write a thorough answer. Let me compile everything.

Medicines for Anemia

Anemia is defined as a below-normal hemoglobin concentration resulting from decreased circulating red blood cells or inadequate hemoglobin content. Treatment is directed at the underlying cause. Here is a complete overview of the drug classes used, based on authoritative pharmacology textbooks.

1. Iron Preparations - Iron Deficiency Anemia (IDA)

Iron deficiency is the most common nutritional deficiency worldwide. Iron is stored as ferritin and transported by transferrin to the bone marrow for hemoglobin synthesis.

Oral Iron Formulations

FormulationBrandElemental Iron (%)Notes
Ferrous sulfateFeosol, Slow Fe20%Standard first-line; most cost-effective
Ferrous fumarateFerro-Sequels33%Highest elemental iron content
Ferrous gluconateFergon12%Less GI irritation
Ferric ammonium citrateIron citrate18%Less bioavailable than ferrous salts
Carbonyl ironIcar98%Slower absorption, lower toxicity
Polysaccharide-iron complexNiferexVariesBetter tolerated
Dosing: CDC recommends 60-120 mg/day of elemental iron in divided doses 2-3x daily. Recent evidence suggests lower doses (40-80 mg/day) or every-other-day dosing may be equally effective with fewer side effects. - Lippincott Illustrated Reviews: Pharmacology, p. 1477
Absorption tip: Iron is absorbed best in the ferrous (Fe²+) form in the duodenum. Acidic gastric conditions keep it soluble. Taking iron with vitamin C enhances absorption. Calcium and antacids reduce absorption.

Parenteral Iron Formulations

Used when oral iron is not tolerated, not absorbed, or the patient needs rapid repletion:
  • Iron dextran (InFed) - must give test dose; risk of anaphylaxis
  • Sodium ferric gluconate (Ferrlecit) - safer profile
  • Iron sucrose (Venofer) - commonly used in dialysis patients
  • Ferric carboxymaltose (Injectafer) - high-dose single infusion
  • Ferumoxytol (Feraheme) - rapid IV infusion option
IV iron is the treatment of choice in the third trimester of pregnancy for severe IDA. - Rosen's Emergency Medicine, p. 839

Adverse Effects of Iron

  • Nausea, vomiting, constipation, dark stools (oral)
  • Anaphylaxis (especially iron dextran - IV)
  • Hemosiderosis with overdose

2. Vitamin B12 (Cyanocobalamin) - Megaloblastic/Pernicious Anemia

Vitamin B12 deficiency causes megaloblastic (macrocytic) anemia and - critically - irreversible neurological damage (subacute combined degeneration of the spinal cord) if untreated.
Mechanism: B12 is essential for conversion of methylmalonyl-CoA to succinyl-CoA and for regeneration of tetrahydrofolate (THF) from methyltetrahydrofolate, which is needed for DNA synthesis.
Preparations:
  • Cyanocobalamin - oral or IM injection
  • Hydroxocobalamin - longer-acting IM form
  • Methylcobalamin - active form, used in neurological disease
Key Clinical Points:
  • Pernicious anemia (lack of intrinsic factor) requires IM/subcutaneous injection as oral absorption is impaired
  • Serum B12 levels <200 pg/mL are diagnostic
  • Must treat with both B12 AND folate empirically if megaloblastic anemia is suspected - folate alone may correct the blood picture but will not prevent neurological damage from B12 deficiency - Lippincott, p. 1483
Adverse effects: Injection site pain, arthralgia, dizziness, headache, rare anaphylaxis. Proton pump inhibitors (PPIs) can reduce oral B12 absorption.

3. Folic Acid (Vitamin B9) - Folate Deficiency Anemia

Folate deficiency causes megaloblastic anemia identical to B12 deficiency in blood picture, but without neurological involvement.
Mechanism: Tetrahydrofolate cofactors are essential for thymidylate (dTMP) synthesis - a key step in DNA replication. Deficiency halts rapidly dividing cells (RBC precursors). - Katzung Basic & Clinical Pharmacology, p. 939
Dosing: Standard dose is 1 mg/day orally. In pregnancy, 400-800 mcg/day is recommended to prevent neural tube defects.
Sources: Liver, yeast, green leafy vegetables. Body stores last only 1-6 months.
Adverse effects: Generally well tolerated; bad taste, nausea, confusion. Cholestyramine may interfere with absorption.

4. Erythropoiesis-Stimulating Agents (ESAs) - Anemia of Chronic Kidney Disease / Chemotherapy

Recombinant forms of erythropoietin stimulate red blood cell production by acting on erythroid progenitor cells via JAK/STAT signaling.
AgentBrandHalf-LifeDosing
Epoetin alfaEpogen, Procrit4-13 hours3x/week SC or IV
Darbepoetin alfaAranesp2-3x longer (more glycosylated)Weekly
Methoxy-PEG-epoetin betaMirceraVery longEvery 2 weeks to monthly
Clinical uses:
  • Anemia of chronic kidney disease (most important indication)
  • Anemia from chemotherapy in cancer patients
  • Perioperative anemia management
  • Myelodysplastic syndrome
Target hemoglobin: Maintained at 10-12 g/dL (exceeding 12 g/dL increases risk of thrombosis and cardiovascular events). - Katzung, p. 941
Key: Patients with disproportionately low EPO levels for their degree of anemia (i.e., CKD patients) respond best. Nearly all CKD patients on ESAs require concurrent iron supplementation.
Adverse effects: Hypertension, edema, thrombosis, stroke, pure red cell aplasia (rare, with anti-EPO antibodies).

5. Drugs for Sickle Cell Anemia

Sickle cell disease (SCD) results from a mutation in the beta-globin gene causing HbS polymerization and RBC sickling.

Hydroxyurea (Hydroxycarbamide)

  • Mechanism: Increases fetal hemoglobin (HbF) production, which dilutes HbS and prevents polymerization. Also reduces neutrophil count and adhesion molecules.
  • Indication: Reduces frequency of painful vaso-occlusive crises, acute chest syndrome, and transfusion need
  • Dosing: Oral, once daily; dose titrated to maximize HbF without excessive myelosuppression
  • Adverse effects: Myelosuppression (leukopenia, thrombocytopenia), teratogenicity, leg ulcers

Crizanlizumab (Adakveo)

  • Mechanism: Humanized monoclonal antibody that blocks P-selectin on activated endothelial cells and platelets, reducing cell-cell adhesion and capillary blockade by sickled RBCs
  • Dosing: IV infusion at weeks 0 and 2, then every 4 weeks; approved age ≥16 years
  • Adverse effects: Infusion reactions, nausea, arthralgia, back pain, pyrexia - Lippincott, p. 1484

Voxelotor (Oxbryta)

  • Mechanism: Binds the alpha chain of HbS and inhibits polymerization by keeping HbS in the oxygenated state (reducing deoxygenated HbS)
  • Dosing: Once-daily oral; approved age ≥12 years; metabolized by CYP3A4
  • Adverse effects: Headache, diarrhea, GI upset - Lippincott, p. 1485

Luspatercept (Reblozyl)

  • TGF-β ligand trap; approved for beta-thalassemia and myelodysplastic syndrome-associated anemia

6. Growth Factors for Neutropenia (Related)

While not treating anemia directly, these support hematopoiesis in bone marrow failure:
AgentBrandAction
Filgrastim (G-CSF)Neupogen, ZarxioStimulates neutrophil production
PegfilgrastimNeulastaLong-acting G-CSF
Sargramostim (GM-CSF)LeukineStimulates multiple myeloid lineages

Summary Table: Anemia Type → Drug of Choice

Anemia TypeFirst-Line Drug(s)
Iron deficiency anemiaOral ferrous sulfate; IV iron for severe/pregnancy
Megaloblastic (B12 deficiency)Cyanocobalamin IM (if pernicious); oral if dietary deficiency
Megaloblastic (folate deficiency)Folic acid 1 mg/day orally
Anemia of chronic kidney diseaseEpoetin alfa or darbepoetin alfa + iron
Sickle cell anemiaHydroxyurea; crizanlizumab; voxelotor
Chemotherapy-induced anemiaEpoetin alfa or darbepoetin alfa
Aplastic anemiaImmunosuppression + eltrombopag; bone marrow transplant

Sources:
  • Lippincott Illustrated Reviews: Pharmacology, Chapter 44 (Drugs for Anemia), pp. 1475-1485
  • Katzung Basic & Clinical Pharmacology, 16th Ed., Chapter 33 (Hematopoietic Agents), pp. 939-941
  • Goodman & Gilman's Pharmacological Basis of Therapeutics, Chapter 13 (Iron, B12, Folate)
  • Rosen's Emergency Medicine (Iron deficiency in pregnancy, p. 839)
This is a shared conversation. Sign in to Orris to start your own chat.